News – Page 1163 – Endpoints News

Biotech billionaire backs a food allergy/nutrition startup; Editas recruits a CMO

9 years ago

André Choulika on gene editing: "If you marry yourself to a technology, you're doomed."

9 years ago

AstraZeneca jettisons another drug, this time grabbing $30M for out-licensing deal

9 years ago

Hold the applause: Big Pharma has little to brag about regarding 2016 R&D productivity

9 years ago

Novartis unveils a new global R&D structure, creating centers in Cambridge, MA and Basel

9 years ago

Novartis is uprooting another research group in ongoing global reorganization

9 years ago

Samsung BioEpis pitches Herceptin biosimilar as parent company hunts $2B IPO; Chiasma CEO is out

9 years ago

Hustling to capture top frontline NSCLC status, Roche scores a ‘breakthrough’ on Alecensa

9 years ago

Amgen joins a marquee list of partners jumping on Nuevolution’s discovery platform

9 years ago

Tobira chairman’s dinner with Brent: Industry chat led to a 3-month pursuit and a stunning $1.7B deal

9 years ago

Soriot’s $3.5B Brilinta dream is dashed by yet another big trial flop for AstraZeneca

9 years ago

Summit shares rocket up, fueled by an $842M pact with Duchenne leader Sarepta

9 years ago

Korean officials launch Hanmi probe in wake of tox reports; Prothena CEO Schenk dies

9 years ago

Sun Pharma takes aim at a crowded market with another IL-23 psoriasis drug from Merck

9 years ago

Merrimack CEO is out as the biotech restructures, chopping its workforce and overhauling R&D

9 years ago

$95M mega-round in hand, Elaine Sullivan sets out to build a European oncology player

9 years ago

AstraZeneca hands off another Amgen-partnered drug in a $1.5B deal with an acquisitive Allergan

9 years ago

Presto! Wall Street magician Vivek Ramaswamy has another instant biotech IPO to sell you

9 years ago

J&J’s IL-23 star guselkumab grabs the spotlight in PhIII psoriasis showdown

9 years ago

Blockbuster performance: Regeneron, Sanofi add stellar PhIII dupilumab data on display at EADV

9 years ago

Following lethal tox report, Boehringer scraps plans for high-speed development, kills $730M Hanmi deal

9 years ago

Threshold blasted, restructures after a PhII failure; SQZ raises $16M

9 years ago

Week in review: Clinton over Trump; the hubs have it; we'll always have Paris

9 years ago

Scoop: Celgene targets a cure for myeloma/lymphoma with $600M EngMab buyout

9 years ago

First page Previous page 1160 1161 116211631164 1165 1166 Next page Last page